Home › Funds › Ironvine Capital Partners, LLC › ABT

Ironvine Capital Partners, LLC position in ABT

ABBOTT LABORATORIES · Health Care

Ironvine Capital Partners, LLC reported holding 14,037 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$1.4M, representing 0.13% of its reported portfolio and ranking #41 among its reported holdings. Ironvine Capital Partners, LLC has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)14.04K sh
Reported value held$1.39M
Portfolio Weight0.13%
First reportedQ3 2023
Last changeHold
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Ironvine Capital Partners, LLC's ABT position evolved

Ironvine Capital Partners, LLC first disclosed a stake in ABT in Q3 2023 at 13,950 shares (US$1.4M). The position peaked in Q2 2025 at 14,037 shares, worth US$1.9M. Across 13 filings, Ironvine Capital Partners, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 11 time(s). The most recent filing (Q3 2026) shows 14,037 shares valued at US$1.4M.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 13.95K $1.35M New
Q4 2023 13.95K $1.54M Hold
Q1 2024 14.04K $1.60M Add
Q2 2024 14.04K $1.46M Hold
Q3 2024 14.04K $1.60M Hold
Q4 2024 14.04K $1.59M Hold
Q1 2025 14.04K $1.86M Hold
Q2 2025 14.04K $1.91M Hold
Q3 2025 14.04K $1.88M Hold
Q4 2025 14.04K $1.76M Hold
Q1 2026 14.04K $1.44M Hold
Q2 2026 14.04K $1.27M Hold
Q3 2026 14.04K $1.39M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.65B), Charles Schwab Investment Management (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has Ironvine Capital Partners, LLC held ABT?

Ironvine Capital Partners, LLC has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Ironvine Capital Partners, LLC's current position in ABT?

As of Q3 2026, Ironvine Capital Partners, LLC holds 14.04K shares of ABT (ABBOTT LABORATORIES), valued at $1.39M, representing 0.13% of its reported portfolio and ranking #41.

Has Ironvine Capital Partners, LLC been buying or selling ABT?

In the latest 13F filing (Q3 2026), Ironvine Capital Partners, LLC held unchanged its position in ABT. The position peaked in Q2 2025 at 14.04K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, Charles Schwab Investment Management, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.